Sarah Faiz1, Jonathan Giovannelli2, Céline Podevin3, Marie Jachiet4, Jean-David Bouaziz4, Ziad Reguiai5, Audrey Nosbaum6, Audrey Lasek7, Marie-Christine Ferrier le Bouedec8, Aurélie Du Thanh9, Nadia Raison-Peyron9, Florence Tetart10, Anne-Bénédicte Duval-Modeste10, Laurent Misery11, François Aubin12, Anne Dompmartin13, Cécile Morice13, Catherine Droitcourt14, Angèle Soria15, Jean-Philippe Arnault16, Juliette Delaunay17, Emmanuel Mahé18, Marie-Aleth Richard19, Amélie Schoeffler20, Jean-Philippe Lacour21, Edouard Begon22, Amélie Walter-Lepage23, Anne-Sophie Dillies24, Sandrine Rappelle-Duruy25, Stéphane Barete26, Nathalia Bellon27, Nathalie Bénéton28, Aude Valois29, Sébastien Barbarot30, Julien Sénéchal31, Delphine Staumont-Sallé32. 1. CHU de Lille, Service de dermatologie, F-59000 Lille, France. 2. CHU de Lille, Service de dermatologie, F-59000 Lille, France; Univ Lille, INSERM U995, Lille Inflammation Research International Center, F-59000, Lille, France. 3. Univ Lille, INSERM U995, Lille Inflammation Research International Center, F-59000, Lille, France. 4. Dermatology Department, and Université́ Paris Diderot Paris VII, Sorbonne Paris Cité APHP, Saint Louis Hospital, Paris, France. 5. Service de dermatologie, Polyclinique Courlancy, Reims, France. 6. Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Pierre Benite, University of Lyon, Lyon, France, CIRI (International Center for Infectiology Research), INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France. 7. Service de dermatologie, Hospital St Vincent de Paul, Groupement des Hôpitaux de l'Institut Catholique de Lille, France. 8. Dermatology Department, University of Clermont-Ferrand, Clermont-Ferrand, France. 9. Service de dermatologie, CHU Montpellier, Univ Montpellier, Montpellier, PCCI, INSERM, Univ Montpellier, Montpellier, France. 10. Department of Dermatology, Inserm U519, Rouen University Hospital, Rouen, France. 11. Department of Dermatology, University Hospital of Brest, Brest, France. 12. Service de dermatologie, Centre Hospitalier Régional Universitaire de Besançon Université de Franche Comté, Besançon, France. 13. Department of Dermatology, Caen University Hospital Center, France. 14. Service de Dermatologie, Centre Hospitalier Universitaire Pontchaillou, Université de Rennes, Rennes, France. 15. Service de Dermatologie et d'Allergologie, Hôpital Tenon, Paris HUEP, APHP, Paris, France Sorbonne Universités Paris, Centre d'Immunologie et des Maladies Infectieuses - Paris (Cimi-Paris), INSERM U1135, Paris, France. 16. Department of Dermatology, Amiens University Hospital, Amiens, France. 17. Service de Dermatologie, CHU d'Angers site Larrey, Angers, France. 18. Department of Dermatology, Hôpital Victor Dupouy Argenteuil, Argenteuil, France. 19. Aix-Marseille University, EA 3279, CEReSS- Health Service Research and Quality of Life Center, Dermatology Department, Timone Hospital, Assistance Publique Hôpitaux de Marseille, 13385, France. 20. Service de Dermatologie, Hôpital Bel Air, Centre Hospitalier Régional Metz-Thionville. 21. Service de Dermatologie, Hôpital l'Archet 2, CHU de Nice, France. 22. Service de Dermatologie, Centre Hospitalier René-Dubos, Pontoise, France. 23. Service de Dermatologie, CHU La Miletrie, Poitiers, France. 24. Service de Dermatologie, Centre Hospitalier de Saint Quentin, France. 25. Service de Dermatologie, Hôpital Joseph Imbert, Centre Hospitalier d'Arles, France. 26. Unité Fonctionnelle de Dermatologie, Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Paris, France. 27. Service de Dermatologie, Hôpital Necker, AP-HP, Paris, France. 28. Service de Dermatologie, Centre Hospitalier de Le Mans, France. 29. Service de Dermatologie, Hôpital d'Instruction des Armées Sainte Anne, Toulon, France. 30. Service de Dermatologie, Hôtel Dieu, CHU de Nantes, France. 31. Service de Dermatologie, Centre de Référence des Maladies Rares de la Peau, Hôpital Saint André, CHU de Bordeaux, France; INSERM U1035 Biothérapie des Maladies Génétiques Inflammatoires et Cancers, Immuno-Dermatologie ATIP AVENIR, Université de Bordeaux, France. 32. CHU de Lille, Service de dermatologie, F-59000 Lille, France; Univ Lille, INSERM U995, Lille Inflammation Research International Center, F-59000, Lille, France. Electronic address: delphine.salle@chru-lille.fr.
Abstract
BACKGROUND: Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. OBJECTIVE: We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. METHODS: We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up. RESULTS: We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10-9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10-9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10-6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs. LIMITATIONS: No control group, missing data. CONCLUSION: This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.
BACKGROUND:Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. OBJECTIVE: We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. METHODS: We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up. RESULTS: We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10-9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10-9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10-6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs. LIMITATIONS: No control group, missing data. CONCLUSION: This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.
Authors: Lieneke F M Ariëns; Daphne S Bakker; Lotte S Spekhorst; Jorien Van der Schaft; Judith L Thijs; Inge Haeck; Annebeth E Flinterman; Marijke Kamsteeg; Marie L A Schuttelaar; Marjolein S De Bruin-Weller Journal: Acta Derm Venereol Date: 2021-10-19 Impact factor: 3.875
Authors: Maya E Kotas; Jérémie Dion; Steven Van Dyken; Roberto R Ricardo-Gonzalez; Claire J Danel; Camille Taillé; Luc Mouthon; Richard M Locksley; Benjamin Terrier Journal: JCI Insight Date: 2021-06-22
Authors: Thanaporn Ratchataswan; Tina M Banzon; Jacob P Thyssen; Stephan Weidinger; Emma Guttman-Yassky; Wanda Phipatanakul Journal: J Allergy Clin Immunol Pract Date: 2021-03